Amyloidosis Clinical Trials

A listing of Amyloidosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 240 clinical trials
Featured trial
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

216 weeks of treatment (A45 Trial) and to determine whether treatment with BAN2401 is superior to placebo in reducing brain amyloid accumulation as measured by amyloid positron emission tomography

dementia
amyloid
mini-mental state examination
mental state examination
  • 26 views
  • 29 Aug, 2022
  • 4 locations
Featured trial
Hypertension Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)

The aim of this study is to determine if lowering blood pressure using FDA approved medication (antihypertensive drugs) alters brain pulsatility and reduces brain amyloid beta protein

angiotensin ii
electrocardiogram
dementia
calcium
beta amyloid protein
  • 114 views
  • 07 Jul, 2022
  • 1 location
Featured trial
Valacyclovir for Mild Cognitive Impairment (VALMCI)

Anti-viral treatment in Mild Cognitive Impairment (MCI) is a Phase II, placebo-controlled, 52-week trial using oral valacyclovir 4 g/day in 50 HSV seropositive, AD biomarker-positive, amnestic mild cognitive impairment (MCI) patients (eMCI and lMCI). The trial will directly address the long-standing viral etiology hypothesis of Alzheimer's disease (AD) which posits …

  • 24 views
  • 08 Sep, 2022
  • 1 location
Featured trial
A PHASE III, MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GANTENERUMAB IN PARTICIPANTS AT RISK FOR OR AT THE EARLIEST STAGES OF ALZHEIMER’S DISEASE

This study is designed to evaluate the efficacy and safety of Gantenerumab in participants at risk for or at the earliest stages of Alzheimer’s Disease (AD) 

Accepts healthy volunteers
  • 4 views
  • 24 Jun, 2022
  • 1 location
Featured trial
B3461087 - Tafamidis

This study is a global, multi-center study designed to estimate the global prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM) within a clinically at risk population [participants with

  • 0 views
  • 09 Jun, 2022
  • 5 locations
Featured trial
Impact of sleep apnea and its treatment on memory and tau accumulation in the brain

may be a modifiable risk factor for AD. This study will build on that by evaluating the effect of PAP treatment on markers of AD, such as amyloid beta (Aβ), Tau levels, and neurofilament light chain

amyloid
mini-mental state examination
mild cognitive impairment
cognitive impairment
  • 0 views
  • 25 Mar, 2022
  • 1 location
Featured trial
Proteins and Brain Networks in Atypical Alzheimer's Disease

Participants will take part in 2-4 study visits including detailed history and neurological exam, pen-&-paper cognitive testing, and functional MRI and PET scans designed to help us understand how different forms of Alzheimer's disease affect brain circuits over time.

amyloid
positron emission tomography
Accepts healthy volunteers
  • 53 views
  • 24 Jan, 2022
  • 1 location
Featured trial
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease

A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease

  • 87 views
  • 25 Mar, 2021
  • 1 location
Featured trial
A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

  • 258 views
  • 08 Dec, 2020
  • 1 location
Cognitive Impairment Registry

The purpose of this study is to develop a recruitment registry of potential drug study participants who may have amyloid, a specific biomarker for Alzheimer's disease, using a phone assessment

Online studies
amyloid
Accepts healthy volunteers
  • 992 views
  • 23 Sep, 2022
  • 1 location
  • Online study